{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=77", "query": { "intervention": "Placebo- C", "page": 77 }, "page_size": 10 }, "pagination": { "page": 77, "page_size": 10, "total_count": 1838, "total_pages": 184, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=78&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo-+C&page=76&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-07T05:30:15.220Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04660890", "title": "A Study of the Cardiac Effects of ALXN2050 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "ALXN2050", "type": "DRUG" }, { "name": "ALXN2050-matching Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Moxifloxacin-matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 39, "start_date": "2020-12-12", "completion_date": "2021-03-16", "has_results": false, "last_update_posted_date": "2021-12-29", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04660890" }, { "nct_id": "NCT06072482", "title": "A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Antineutrophil Cytoplasmic Antibody-associated Vasculitis" ], "interventions": [ { "name": "Avacopan", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 300, "start_date": "2024-02-07", "completion_date": "2036-12-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 62, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Surprise, Arizona + 57 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072482" }, { "nct_id": "NCT01448824", "title": "A Study of LY2484595 on Pharmacokinetics in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "LY2484595", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 82, "start_date": "2011-10", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2019-04-02", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 2, "location_summary": "Daytona Beach, Florida • Dallas, Texas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01448824" }, { "nct_id": "NCT01752985", "title": "Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Kidney Disease" ], "interventions": [ { "name": "BMS-813160", "type": "DRUG" }, { "name": "Placebo matching with BMS-813160", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 319, "start_date": "2013-03-18", "completion_date": "2015-06-30", "has_results": true, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 43, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01752985" }, { "nct_id": "NCT04208178", "title": "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced HER2+Breast Cancer" ], "interventions": [ { "name": "Alpelisib", "type": "DRUG" }, { "name": "Alpelisib matching Placebo", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Pertuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 19, "start_date": "2020-07-16", "completion_date": "2027-02-26", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 2, "location_summary": "Fayetteville, Arkansas • Los Angeles, California", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04208178" }, { "nct_id": "NCT04687449", "title": "Curcumin in Management of Chronic Obstructive Pulmonary Disease", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "COPD" ], "interventions": [ { "name": "Curcumin therapy", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Standard care", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Danbury Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "40 Years to 89 Years" }, "enrollment_count": 120, "start_date": "2022-01-01", "completion_date": "2023-12-15", "has_results": false, "last_update_posted_date": "2021-07-09", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 1, "location_summary": "Danbury, Connecticut", "locations": [ { "city": "Danbury", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04687449" }, { "nct_id": "NCT01371578", "title": "Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "GS-5885 tablet", "type": "DRUG" }, { "name": "GS-9451 tablet", "type": "DRUG" }, { "name": "peginterferon alfa-2a", "type": "BIOLOGICAL" }, { "name": "ribavirin tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 163, "start_date": "2011-07", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2014-02-11", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 54, "location_summary": "Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01371578" }, { "nct_id": "NCT03049735", "title": "LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 388, "start_date": "2017-04-26", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 76, "location_summary": "Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049735" }, { "nct_id": "NCT06153355", "title": "A First-In-Human Study of LY3839840 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY3839840", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 140, "start_date": "2023-12-04", "completion_date": "2025-05-22", "has_results": false, "last_update_posted_date": "2025-06-06", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 2, "location_summary": "Anaheim, California • Madison, Wisconsin", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06153355" }, { "nct_id": "NCT04166058", "title": "Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Irritable Bowel Syndrome With Constipation", "Functional Constipation" ], "interventions": [ { "name": "Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers)", "type": "DRUG" }, { "name": "Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Years to 18 Years" }, "enrollment_count": 381, "start_date": "2019-11-19", "completion_date": "2025-06-05", "has_results": true, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-11-07T05:30:15.220Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 50 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Foley", "state": "Alabama" }, { "city": "Saraland", "state": "Alabama" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04166058" } ] }